SCI Abstract

search
Prophylactic management of patients with von Willebrand disease
Prophylactic management of patients with von Willebrand disease
Von Willebrand disease, the most common inherited bleeding disorder that affects both males and females, is due to quantit...
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mita...
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant p...
Bortezomib in autoimmune hemolytic anemia and beyond
Bortezomib in autoimmune hemolytic anemia and beyond
Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multip...
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma
1. Rodriguez-Abreu, D, Bordoni, A, Zucca, E. Epidemiology of hematological malignancies. Ann Oncol 2007; 18(Suppl. 1): i3–...
Current and emerging treatment options in primary mediastinal B-cell lymphoma
Current and emerging treatment options in primary mediastinal B-cell lymphoma
Previously considered a subtype of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) is n...
Emicizumab in acquired haemophilia A: about two clinical cases and literature review
Emicizumab in acquired haemophilia A: about two clinical cases and literature review
Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed agains...
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
The pathological increase of clonal IgM in Waldenström macroglobulinemia can be associated with acquired von Willebrand sy...
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of...
Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data
Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data
Background:DDX41 serves as a DNA sensor in innate immunity and mutated DDX41 is pathogenic, mainly for myeloid neoplasms.M...
The use of tafasitamab in diffuse large B-cell lymphoma
The use of tafasitamab in diffuse large B-cell lymphoma
Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have ...
Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies
Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies
Background and aims:The application of QuantiFERON-TB Gold in-Tube (QFT-GIT) in patients with haematological malignancies ...
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
Aims:This study quantifies the value of survival gains attributable to novel treatments approved since 2003 for United Sta...
Treosulfan-based conditioning for inborn errors of immunity
Treosulfan-based conditioning for inborn errors of immunity
Inborn errors of immunity (IEI) are inherited disorders that lead to defects in the development and/or function of the imm...
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications
Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of ...
The role of tazemetostat in relapsed/refractory follicular lymphoma
The role of tazemetostat in relapsed/refractory follicular lymphoma
Large strides have been made in the treatment of follicular lymphoma (FL) over the last few years. Although the majority o...
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) continues to make its way in the tre...